MX355469B - Complejos de proteinas de citomegalovirus. - Google Patents
Complejos de proteinas de citomegalovirus.Info
- Publication number
- MX355469B MX355469B MX2014015496A MX2014015496A MX355469B MX 355469 B MX355469 B MX 355469B MX 2014015496 A MX2014015496 A MX 2014015496A MX 2014015496 A MX2014015496 A MX 2014015496A MX 355469 B MX355469 B MX 355469B
- Authority
- MX
- Mexico
- Prior art keywords
- complexes
- complex
- hcmv
- cytomegalovirus proteins
- disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un complejo de proteína de membrana de citomegalovirus humano (HCMV) aislado, en donde el complejo comprende gH, gL y por lo menos una glicoproteína de HCMV. En algunas modalidades el complejo consiste de gH, gL y gO. En otras modalidades el complejo consiste de gH, gL, pUL128, pUL130 y pUL131A. La descripción también proporciona procesos para expresar y purificar los complejos y usos subsecuentes de los complejos en composiciones inmunogénicas y vacunas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668975P | 2012-07-06 | 2012-07-06 | |
US201361770257P | 2013-02-27 | 2013-02-27 | |
PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014015496A MX2014015496A (es) | 2015-03-06 |
MX355469B true MX355469B (es) | 2018-04-19 |
Family
ID=48783208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015496A MX355469B (es) | 2012-07-06 | 2013-06-29 | Complejos de proteinas de citomegalovirus. |
Country Status (17)
Country | Link |
---|---|
US (4) | US9683022B2 (es) |
EP (1) | EP2869843B1 (es) |
JP (3) | JP2015522581A (es) |
KR (1) | KR20150031322A (es) |
CN (1) | CN104853771A (es) |
AU (1) | AU2013286093B2 (es) |
CA (1) | CA2878344A1 (es) |
ES (1) | ES2753138T3 (es) |
GB (1) | GB2513768B (es) |
HK (1) | HK1210037A1 (es) |
IL (1) | IL236261A0 (es) |
IN (1) | IN2014KN02929A (es) |
MX (1) | MX355469B (es) |
RU (1) | RU2015103891A (es) |
SG (1) | SG11201408328VA (es) |
WO (1) | WO2014005959A1 (es) |
ZA (1) | ZA201409364B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104853771A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
ES2719720T3 (es) | 2012-07-27 | 2019-07-12 | Hope City | Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014359276B2 (en) * | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
WO2015161926A1 (en) * | 2014-04-23 | 2015-10-29 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
PE20170301A1 (es) * | 2014-05-08 | 2017-03-30 | Pfizer | Medios y metodos para el tratamiento cmv |
EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
WO2017044895A2 (en) | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
CA3010974A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2018193307A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
WO2019020480A1 (en) * | 2017-07-24 | 2019-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES |
CN111163799A (zh) * | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
AU2018331874B2 (en) * | 2017-09-13 | 2022-06-02 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
JP2021523937A (ja) | 2018-05-04 | 2021-09-09 | スパイバイオテック・リミテッド | ワクチン組成物 |
CA3116175A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
US11629172B2 (en) * | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US20230201334A1 (en) | 2019-07-24 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
TW202413391A (zh) | 2020-06-21 | 2024-04-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US20230398211A1 (en) | 2020-10-28 | 2023-12-14 | Sanofi Pasteur | Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof |
EP4298444A2 (en) * | 2021-02-24 | 2024-01-03 | Pfizer Inc. | Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0452364B1 (en) | 1988-12-22 | 2002-05-22 | Genentech, Inc. | Method for preparing water soluble polypeptides |
KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
EP0541721A4 (en) | 1990-08-02 | 1993-12-29 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
WO2012034025A2 (en) | 2010-09-09 | 2012-03-15 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
JP2013544504A (ja) * | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
KR20140007404A (ko) * | 2011-01-31 | 2014-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 신규 허피스 항원을 암호화하는 핵산 분자, 이것을 포함하는 백신 및 이것의 사용 방법 |
JP6120839B2 (ja) * | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
ES2705498T3 (es) * | 2011-08-31 | 2019-03-25 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para administración de ARN que codifica inmunógeno |
CN104853771A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en active Application Filing
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Application Discontinuation
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2015
- 2015-11-04 HK HK15110880.5A patent/HK1210037A1/xx unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2015522581A (ja) | 2015-08-06 |
ES2753138T3 (es) | 2020-04-07 |
JP2017192400A (ja) | 2017-10-26 |
MX2014015496A (es) | 2015-03-06 |
KR20150031322A (ko) | 2015-03-23 |
US9683022B2 (en) | 2017-06-20 |
AU2013286093A1 (en) | 2015-02-12 |
US20170320916A1 (en) | 2017-11-09 |
AU2013286093B2 (en) | 2018-01-04 |
IN2014KN02929A (es) | 2015-05-08 |
IL236261A0 (en) | 2015-02-26 |
US20160159864A1 (en) | 2016-06-09 |
WO2014005959A1 (en) | 2014-01-09 |
RU2015103891A (ru) | 2016-08-27 |
US20190211064A1 (en) | 2019-07-11 |
CN104853771A (zh) | 2015-08-19 |
US10287322B2 (en) | 2019-05-14 |
GB2513768B (en) | 2015-04-15 |
EP2869843A1 (en) | 2015-05-13 |
ZA201409364B (en) | 2017-08-30 |
JP2017192399A (ja) | 2017-10-26 |
US20220106364A1 (en) | 2022-04-07 |
GB2513768A (en) | 2014-11-05 |
GB201413863D0 (en) | 2014-09-17 |
SG11201408328VA (en) | 2015-02-27 |
HK1210037A1 (en) | 2016-04-15 |
CA2878344A1 (en) | 2014-01-09 |
EP2869843B1 (en) | 2019-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2513768A (en) | Complexes of cytomegalovirus proteins | |
MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
TN2014000438A1 (en) | Anti-fcrn antibodies | |
WO2016046234A3 (en) | Recombinant phe-free proteins for use in the treatment of phenylketonuria | |
MX2017009538A (es) | Antigenos de citomegalovirus y su uso. | |
WO2011152566A3 (en) | Composition for inducing proliferation or accumulation of regulatory t cells | |
PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
EP3967323A3 (en) | Hiv vaccine | |
WO2014035475A8 (en) | Methods to control protein heterogeneity | |
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
WO2014011901A3 (en) | Methods and compositions for delivery of biologics | |
IN2015DN02826A (es) | ||
MY156697A (en) | Modified tuberculosis antigens | |
TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
EP3079718A4 (en) | Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines | |
MX354516B (es) | Vectores que codifican el factor de viabilidad de conos derivado de bastones. | |
MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
WO2012054929A3 (en) | Use of human serum albumin to decrease antigenicity of therapeutic proteins | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
IN2015DN02546A (es) | ||
PH12016500753A1 (en) | Antibodies specific to fcrn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |